Hi [[ session.user.profile.firstName ]]

Life Sciences

  • Searching for adverse effects of medical devices in MEDLINE and Embase
    Searching for adverse effects of medical devices in MEDLINE and Embase Dr Su Golder NIHR Research Fellow, Health Sciences, University of York Recorded: Oct 18 2018 44 mins
    In this webinar, Dr Su Golder NIHR Research Fellow, Health Sciences, at the University of York will discuss:

    - Importance of medical device adverse effects
    - Problems with searching for medical device adverse effects
    - Approaches to searching for medical device adverse effects
    - Research into search filters for medical device adverse effects

    Dr Su Golder is a qualified information specialist with over 20 years' experience. She has worked in lots of different settings and has a wide breadth of experience in supporting systematic reviews of healthcare interventions. She has specialist expertise in systematic review methodology and systematic reviews of adverse effects and has taught in this field. Her PhD on optimising the retrieval of adverse effects data was funded by the MRC and has made an important contribution to the retrieval of information on adverse effects both nationally and internationally. Her current research is on the use of unpublished data, text mining and social media to maximise the efficiency and effectiveness of the retrieval of adverse effects data and has been funded by the National Institute for Health Research (NIHR) and began in January 2015 on a part-time basis.
  • Improved Synthetic Planning with Reaxys Procurement Integration- 5pm CET
    Improved Synthetic Planning with Reaxys Procurement Integration- 5pm CET Scott Hutton, Commercial Director and Prima Sung, Sr. Solution Marketing Manager Recorded: Oct 17 2018 50 mins
    Laboratory scientists face many practical challenges in implementing a desired chemical synthesis. One major challenge is the ability to access accurate information on what starting materials are available in a company’s local inventory, as well as which suppliers may be used to purchase desired chemicals. Once materials are identified, how long will it take to get them? What is the company’s negotiated price for each material?

    Besides being clever scientists, medicinal chemists must be master logistics planners coordinating all the materials and documentation necessary to perform chemical synthesis on an ongoing basis. Elsevier understands the chemist’s synthetic work flow and has taken steps with Reaxys to enable integration with local chemical inventory and purchasing systems.

    Please join us for this webinar, in which we will focus on:

    - The challenges of identifying and purchasing critical starting materials for chemical synthesis planning
    - How your procurement system can be integrated with Reaxys to make this process easier while saving the organization time and money.
    - How additional data from your systems can be integrated with Reaxys to improve workflows and accelerate discovery.
  • Extractables and leachables testing using a Quality Risk Management approach
    Extractables and leachables testing using a Quality Risk Management approach Dhaval Tapiawala, Pfizer and Satish Kumar Mohanvelu Life Sciences Management Professional at MilliporeSigma Recorded: Oct 17 2018 79 mins
    • Understanding extractables and leachables for better adoption of single use systems
    • Ensuring safety of drug through determining the level of leachables throughout product life cycle
    • Case Study of implementation of standardized testing protocol
  • Improved Synthetic Planning with Reaxys Procurement Integration - 9am CET
    Improved Synthetic Planning with Reaxys Procurement Integration - 9am CET Scott Hutton, Commercial Director and Prima Sung, Sr. Solution Marketing Manager Recorded: Oct 17 2018 45 mins
    Laboratory scientists face many practical challenges in implementing a desired chemical synthesis. One major challenge is the ability to access accurate information on what starting materials are available in a company’s local inventory, as well as which suppliers may be used to purchase desired chemicals. Once materials are identified, how long will it take to get them? What is the company’s negotiated price for each material?

    Besides being clever scientists, medicinal chemists must be master logistics planners coordinating all the materials and documentation necessary to perform chemical synthesis on an ongoing basis. Elsevier understands the chemist’s synthetic work flow and has taken steps with Reaxys to enable integration with local chemical inventory and purchasing systems.

    Please join us for this webinar, in which we will focus on:

    - The challenges of identifying and purchasing critical starting materials for chemical synthesis planning
    - How your procurement system can be integrated with Reaxys to make this process easier while saving the organization time and money.
    - How additional data from your systems can be integrated with Reaxys to improve workflows and accelerate discovery.
  • Digital therapeutics and healthcare innovation
    Digital therapeutics and healthcare innovation Roberto Ascione, Healthware International, Megan Coder, Digital Therapeutics Alliance, Pierre Leurent, Voluntis Recorded: Oct 12 2018 70 mins
    Digital technology is transforming the way that healthcare is practiced and delivered, with areas like digital therapeutics forging ahead to complement traditional medical approaches and augment patient care.

    The development of software applications that are available with a prescription took a major step forward last year with the first FDA approval for a mobile medical application with both a safety and efficacy label.

    At the same time as digital therapeutics are breaking new ground there’s a whole ecosystem of digital health innovations that are also tackling healthcare issues in new and imaginative ways.

    From doctor-patient communication to managing healthcare costs, from healthcare monitoring to clinician workflow, the range of digital health tools and services available is rapidly expanding.

    We’ll be looking at how digital and traditional approaches to medicine are being combined to improve patient outcomes.

    This free webinar will also see our expert panel:
    •Consider the current state of play with digital therapeutics and what the future holds for them
    •Discuss how to harness healthcare innovations to involve and engage patients
  • Engaging with patient communities – tailoring approaches
    Engaging with patient communities – tailoring approaches Jamie Bearse, Thomas Farrington, Chuck Strand and Jenny Kite Recorded: Oct 11 2018 62 mins
    Change Together will be presenting a live webinar with leading figures from the patient advocacy community, who will discuss communication and engagement as well as the different approaches advocacy groups can take to address the unique challenges of their communities. This will be helpful for all advocates, as we hear and learn from our expert panel how their organizations are bringing about change.
  • Actavis and equivalence – where are we now?
    Actavis and equivalence – where are we now? Douglas Drysdale, partner, HGF Recorded: Oct 11 2018 63 mins
    The UK Supreme Court's 2017 decision in Actavis v Eli Lilly introduced a doctrine of equivalents into UK law. In this webinar, we'll discuss the implications of that decision and look at how it is being applied in other cases in the UK courts.
  • Lighten Up!  Long-term imaging with ultra-bright, organic AIE cell trackers
    Lighten Up! Long-term imaging with ultra-bright, organic AIE cell trackers Liu Bin, PhD,Department Head - Department of Chemical and Biomolecular Engineering, National University of Singapore Recorded: Oct 10 2018 33 mins
    With the recent discovery of a special class of organic compounds with aggregation-induced emission (AIE) characteristics, new opportunities have opened for in vitro and in vivo imaging. In combination with advanced polymer encapsulation technologies, AIE compounds are now available as LuminiCell ultra-bright, organic nanoparticles that enable long-term cell tracking and imaging for applications such as cancer research and stem cell biology.
  • Realising the biotech promise: addressing the path to market
    Realising the biotech promise: addressing the path to market Steve Bates, BIA, Sheela Upadhyaya, NICE, Fred Jacobs, TYG, Dean Summerfield, IQVIA Recorded: Oct 9 2018 72 mins
    Now more than ever before, Biotech is the engine for innovation in medicine, finding, creating and delivering ground-breaking treatments to patients.

    The journey from molecule discovery and development through valuation, funding, regulatory and commercialisation can be a long and complex road to travel though.

    These companies have to navigate a rapidly changing and increasingly complex landscape from pre-clinical valuation through foresight and planning at every stage of the asset life cycle - and at a time when Brexit adds uncertainty about regulatory approval and launch windows.

    Working with IQVIA, pharmaphorum has assembled a specialist panel to discuss these challenges and the most effective routes to overcoming them.

    On Tuesday 9th October at 15:00 BST / 10:00 EST we will present a free-to-attend online debate which will bring these experts together to deliver insight on topics such as market valuation, financing, navigating regulatory hurdles, patient engagement & HTA strategies through to successful commercialisation.
  • How Clinical Laboratories Save Money & Help Physicians Become Patient-Centric
    How Clinical Laboratories Save Money & Help Physicians Become Patient-Centric Jeffrey Reid, Tony McCraney Recorded: Oct 9 2018 30 mins
    Value-based healthcare policies continue driving the healthcare market away from a fee-for-service model and more toward an enhanced patient management model. Therefore, physicians need to become more patient-centric to strengthen their competitiveness in the marketplace.

    While this market shift continues expanding, physicians depend heavily on diagnostic testing to aid patient therapy and treatment in a timely manner. In return, the patient's chronic disease outcome may drastically improve.

    Since clinical laboratories analyze and generate the test results, they are one of the most vital pieces in this dynamic market shift. The laboratory decision makers will need to implement strategies to enhance laboratory efficiencies, keep up with the ever-growing sample volumes and counter the decline in test reimbursements.

    Join this webinar to learn…

    …the current market trends that are impacting clinical laboratories.

    …how clinical laboratories can become more competitive in the marketplace.

    …ways clinical laboratories can provide high quality test results and reduce overall operating costs via a versatile and fully automated chemistry analyzer.

    Presenters:
    Jeffrey Reid
    MedTest Dx, Director of Business Development

    Tony McCraney
    Premier Medical laboratory, Chemistry Supervisor


    **All Questions Will Be Answered After the Webinar**
  • Impact of Depth Filtration on Disulfide Bond Reduction during Downstream Process
    Impact of Depth Filtration on Disulfide Bond Reduction during Downstream Process Brian O’ Mara, Senior Research Scientist I, Bristol-Myers Squibb and Alexei Voloshin, Global Application Strategy Specialist Recorded: Oct 8 2018 79 mins
    Title:Impact of Depth Filtration on Disulfide Bond Reduction during Downstream Processing of Monoclonal Antibodies from CHO Cell Cultures

    Presenters: Brian O'mara, Senior Research Scientist I, Bristol-Myers Squibb and Alexei Voloshin, Global Application Strategy Specialist
    • Understand disposable depth filtration technology used in the recovery of antibodies from CHO cell cultures as a unit operation leading to cellular lysis under particular operational conditions • Study how cellular lysis occurring during depth filtration releases endogenous REDOX regulating enzymes and co-factors into the clarified harvest, resulting in the reduction of antibody interchain disulfide bonds • Classify critical process parameters and quality attributes of the clarified harvest to be monitored during filtration development • Discuss risk mitigation strategies to control antibody reduction when using single-use disposable technologies in the recovery of antibodies from CHO cells
  • Implementing CMC Strategies for scale-up operations in biologics manufacturing
    Implementing CMC Strategies for scale-up operations in biologics manufacturing Dr Anita Krishnan, Lupinand -Dr. Annu Uppal, Global Demo Lead and Advanced Workflow Specialist at SCIEX Recorded: Oct 5 2018 73 mins
    Biotechnological products are so complex, that manufacturing biologics which are both cost-effective and with best product quality, is a technical challenge. In the context of biosimilar manufacturing at each step, the sponsor should evaluate the extent to which there is residual uncertainty about the biosimilarity of the proposed product. Often there is remnant quality difference beyond the capability of process to address. In such instances, in-depth understanding of the process, impurities, analytical methods, the mechanism of action (MOA) of the drug substance and clinical relevance of any observed structural differences, will help in implementing novel CMC strategies. This talk will examine the elements of biopharmaceutical development that lead to successful licensure of biotherapeutics.
  • A full overview of different technologies to increase HPLC efficiency & speed
    A full overview of different technologies to increase HPLC efficiency & speed Dr. Frank Michel, Analytical & Chromatography Scientific Advisor, Merck KGaA, Darmstadt, Germany Recorded: Oct 4 2018 64 mins
    In the recent decades the demand for higher separation efficiency or higher speed in HPLC has increased strongly. The response to this demand was answered by modern HPLC technologies such as UHPLC with sub-2 µm particles, monolithic silica or Fused-Core™ particles. This webinar provides an overview on the factors that influence the speed of the HPLC method. It introduces the different approaches of small HPLC particles, Fused-Core (also known as core-shell) particle technology and monolithic silica rods and discusses the advantages and disadvantages of each approach. The presentation covers the theoretical background of these technologies and multiple examples of applications.
  • From Homegrown to Commercial PIM: Transition Strategies for Success
    From Homegrown to Commercial PIM: Transition Strategies for Success Alison Tran, Client Partner, EIS; Chantal Schweizer, Principal Consultant, EIS Recorded: Sep 27 2018 54 mins
    As your business and product data complexity grows, so too may your need for an enhanced PIM system that accounts for numerous operating units, separate companies, global operations, and more.

    How do you judge whether you are ready to jump from your homegrown solution? And if you’re ready to make the jump, what is the best path to ensure that you transition from one system to another successfully?

    In this session you will learn:

    * The milestones that signal your readiness to take on a commercial PIM
    * Best practices when making the transition to a commercial PIM
    * How to align your PIM strategy to a logical data model

    SPEAKERS
    Alison Tran, EIS, Client Partner, brings over 14 years of business and technology consulting experience in technology adoption, software implementation, organizational redesign, change management and process reengineering.
    Chantal Schweizer, EIS, Principal Consultant, a senior information organization professional with over 10 years experience in product information and taxonomy design.
  • Making Process Personal
    Making Process Personal Paul Holmes-Higgins, Micha Kiener Recorded: Sep 27 2018 32 mins
    Flowable is a digital platform for business process and case management solutions that connect users and automate systems. We are helping global companies find new ways to engage with their customers, partners and employees.
  • Developability Assessment of Therapeutic Proteins – A Toolbox for Tackling Incre
    Developability Assessment of Therapeutic Proteins – A Toolbox for Tackling Incre Thorsten Lorenz, Team Head Developability Assessment Biologics, Novartis and Beate Kern, Product Manager, NanoTemper Recorded: Sep 27 2018 65 mins
    Title: Developability Assessment of Therapeutic Proteins – A Toolbox for Tackling Increasing Complexity
    Presenter: Thorsten Lorenz, Team Head Developability Assessment Biologics, Novartis

    Early lead selection of biotherapeutics during preclinical development requires careful characterization of a variety of molecule properties to reduce the risk for encountering unexpected obstacles during technical development. The diversity and increasing complexity of new protein formats requires a change from former platform approaches often applied for antibodies, to project specific strategies. The developability assessment concept applied at Novartis combines information addressing various technical areas, such as expression, aggregation propensity, process fit, stability, physicochemical properties, etc. This integrated concept prior to lead selection provides a thorough, yet resource efficient approach to select suitable candidates.
  • Tracking technology trends to maximise commercialisation value
    Tracking technology trends to maximise commercialisation value Mireya McKee CEO of McKee Innovation Consulting Recorded: Sep 26 2018 55 mins
    Technology commercialisation at its core requires for an invention to be applied to a use case in a specific market. Doing this successfully will ensure that you are getting ROI out of your research and inventions. Mireya McKee has over 16 years experience in research, academia and commercialisation and will be talking about how she utilises technology trends to maximise commercialisation value.

    Some of the topics discussed in this webinar will be:

    * How to track technology trends
    * What can patents tell us about technology trends
    * Technology adoption cycle
    * How technology readiness levels can affect commercialisation opportunities
  • Multiplex immunoassay detection of Alzheimer’s disease biomarkers
    Multiplex immunoassay detection of Alzheimer’s disease biomarkers Anthony Saporita, PhD Recorded: Sep 26 2018 41 mins
    Monitoring protein biomarkers in cerebrospinal fluid (CSF) of patients with Alzheimer’s Disease (AD) has been highly beneficial to understanding disease progression. While several CSF biomarkers can reproducibly distinguish normal and diseased samples, CSF is a difficult biological fluid to obtain in research studies. The need for blood-based biomarkers of AD has driven a continuous search for novel candidates. Here we report the development of a multiplex immunoassay to quantitatively measure seven proteins present in both CSF and blood that are involved in neurological disease: Neurogranin, TREM2, ApoE4, FABP3, Ferritin, angiogenin, and prion protein. Notably, presence of the APOE4 allele is prominently associated with an increased risk for AD, in comparison to the APOE2 and APOE3 alleles. Although these ApoE isoforms differ at only one or two amino acids, our assay distinguished ApoE4 with minimal cross-reactivity. Using this novel immunoassay, we measured these 7 biomarkers in CSF, plasma, and serum from AD patients and healthy controls. Additionally, we developed an ultrasensitive Single Molecule Counting (SMCTM) assay for amyloid beta 1-42 (Aβ42). This kit could detect the Aβ42 peptide in CSF and plasma at sub-pg/mL concentrations. This study demonstrates the value of evaluating both novel and established biomarkers of neurodegeneration across distinct sample types.
  • Understanding and Optimizing Headspace SPME
    Understanding and Optimizing Headspace SPME Robert E. Shirey, Principal R&D Scientist, Merck KGaA, Darmstadt Germany Recorded: Sep 26 2018 59 mins
    Solid phase microextraction (SPME) is a fast, economical, solvent-free, quantitative method for extraction of analytes out of a sample. When analysing volatile and semi-volatile analytes, extraction may be performed in the headspace, or space surrounding the sample, avoiding direct immersion of the fiber. This presentation will provide method development guidance for the extraction and quantification of analytes using headspace SPME. The mechanism of headspace SPME will be explained in detail. Methods for enhancing extraction efficiency will be described. Advantages of headspace SPME over other common extraction methods will be highlighted.
  • Multiplex immunoassay detection of Alzheimer’s disease biomarkers: Session 1
    Multiplex immunoassay detection of Alzheimer’s disease biomarkers: Session 1 Anthony Saporita, PhD Recorded: Sep 26 2018 41 mins
    Monitoring protein biomarkers in cerebrospinal fluid (CSF) of patients with Alzheimer’s Disease (AD) has been highly beneficial to understanding disease progression.  While several CSF biomarkers can reproducibly distinguish normal and diseased samples, CSF is a difficult biological fluid to obtain in research studies.  The need for blood-based biomarkers of AD has driven a continuous search for novel candidates.  Here we report the development of a multiplex immunoassay to quantitatively measure seven proteins present in both CSF and blood that are involved in neurological disease:  Neurogranin, TREM2, ApoE4, FABP3, Ferritin, angiogenin, and prion protein.  Notably, presence of the APOE4 allele is prominently associated with an increased risk for AD, in comparison to the APOE2 and APOE3 alleles.  Although these ApoE isoforms differ at only one or two amino acids, our assay distinguished ApoE4 with minimal cross-reactivity. Using this novel immunoassay, we measured these 7 biomarkers in CSF, plasma, and serum from AD patients and healthy controls.  Additionally, we developed an ultrasensitive Single Molecule Counting (SMCTM) assay for amyloid beta 1-42 (Aβ42).  This kit could detect the Aβ42 peptide in CSF and plasma at sub-pg/mL concentrations.  This study demonstrates the value of evaluating both novel and established biomarkers of neurodegeneration across distinct sample types.
  • Duolink PLA Technology: How to detect and quantify protein interactions
    Duolink PLA Technology: How to detect and quantify protein interactions Cláudia Emanuele, Ph.D. and Paola Braga Recorded: Sep 20 2018 68 mins
    Duolink® proximity ligation assay (PLA) technology allows you to visualize protein interactions with cellular localization and quantities by amplifying signals corresponding to single and post-translational protein events. With 1000x sensitivity and high specificity, this protein detection technology allows to visualize protein functions, all within a native cell. The PLA method provides:
    •Visual protein interactions
    −Both stable and transient
    •Endogenous protein detection
    −No overexpression or genetic manipulation
    •High specificity
    −Use of two antibodies/probes eliminates false positives
    −Single molecule sensitivity
    •Rolling circle amplification makes proteins visible
    •No special equipment needed
    −Standard immunofluorescence methods

    This webinar will review how to work with PLA technology and provide an overview of their potential along with example applications.
  • Librarians’ Role in Evidence-Based Medicine Education for Healthcare Policymaker
    Librarians’ Role in Evidence-Based Medicine Education for Healthcare Policymaker Maylene Qiu, Systematic Review Coordinator and Clinical Liaison Librarian at Biomedical Library, University of Pennsylvania Recorded: Sep 19 2018 54 mins
    NOTE: NEW DATE!

    The practice of evidence-based medicine (EBM) requires retrieving the knowledge from ever-increasing volume of literature. Librarians have supported EBM by offering information searching skills and various tailored training programs.

    While users’ needs constantly drive library’s teaching activities, customizable EBM teaching modules have been developed to respond to different needs of library's constituencies, particularly the policy makers within a university’s healthcare system. This involvement creates a new avenue to convey library’s value.

    About the speaker Maylene Qiu

    Maylene is responsible for developing and providing systematic review services for the patrons principally from the health sciences schools at UPenn and the UPenn Healthcare System. She also serves as the Clinical Liaison Librarian promoting evidence-based medicine information resources and services.

    Before coming to Penn, Maylene was Clinical Reference Librarian at Quillen College of Medicine Library at East Tennessee State University, where she provided services for the clinicians at the Point-of-Care.

    Prior to the library field, she has 10-year experience in pharmaceutical science obtained from working in China, Japan, and Canada. In that career, she commercialized several products in nutrition and agriculture. She earned a B.S. in Pharmaceutical Science from the Nanjing University of Chinese Traditional Medicine, and an M.A. in the Library and Information Science from the University of Wisconsin – Madison.
  • PD-L1 Assays – More than just an antibody
    PD-L1 Assays – More than just an antibody Dr. Michael Flores Recorded: Sep 18 2018 33 mins
    In this webinar, Dr. Flores will summarize the PD-L1 testing assays currently available on market and address the importance of understanding the different scoring algorithms developed for their respective PD-1/PD-L1 immunotherapies. You will learn about a system approach to testing and where to find further information on how to appropriately interpret the specific PD-L1 assay you are working with.
  • Machine Learning and AI with Liferay
    Machine Learning and AI with Liferay Piotr Swiniarski Recorded: Sep 18 2018 43 mins
    Even if both terms are often used in connection with each other, they do not denote the same thing. Nevertheless, Artificial Intelligence (AI) and Machine Learning are already present in our everyday lives: from smart home entertainment solutions such as Amazon Alexa to partially self-driving cars, personalized product recommendations in online commerce, or fraud detection in the financial sector. Also, companies are already heavily committed to the commercial use of this revolutionary technology.

    A practical and simple way for small to medium-sized companies to take advantage of Machine Learning in their day-to-day business is to use it in combination with an enterprise portal software such as Liferay. The idea behind this is that Machine Learning can be used to automate numerous functions and workflows and thus make them more efficient.

    Companies should rely on a competent development partner when using digital platforms such as Liferay. In addition to professional advice on the selection and design of the most suitable solution, you should ensure that this partner provides complete support for the complex integration and ad-aptation of third-party systems.

    The development partner should also ensure that the portal is always up to date and should provide comprehensive support for migration and upgrades as well as training for administrators and users.

    Liferay offers an ideal platform for deploying Machine Learning applications today, and numerous open source solutions are already available for the development of corresponding models. Best of all, companies can easily leverage their existing IT environment without having to invest in additional hardware or server infrastructure.
  • DSF and FTIR as methods for the identification and characterization
    DSF and FTIR as methods for the identification and characterization Marina Kirkitadze , Deputy Director, Head of Biophysics & Conformation Unit, Analytical R&D Biochemist & Kristen Kalbfleisch Recorded: Sep 18 2018 71 mins
    The focus of this presentation is the application of Fourier Transform Infrared Spectroscopy (FTIR) and Differential Scanning Fluorimetry (DSF) methods to characterize vaccine components and their stability. Additionally, FTIR can be applied for the identification of final vaccine products, and DSF can be used to distinguish different formulations of vaccine candidates. These methods, when used in conjuction, provide valuable information regarding characterization and stability in the final stages of vaccine manufacturing.
  • 3D Organ-on-a-chip Applications Using the AIM Biotech Chip
    3D Organ-on-a-chip Applications Using the AIM Biotech Chip Kuan Chee Mun and Mahama Aziz Traore Oct 22 2018 1:00 pm UTC 75 mins
    In vitro 3D cell culture models have emerged as a bridge between conventional 2D cell culture models and the complex & expensive in vivo animal models. By analyzing and comparing the biological behavior of tissues embedded in 3 dimensional hydrogels, results are significantly different from classic 2D cell culture in terms of proliferation, morphology, drug response and gene expression. These differences have been attributed to the topographically complex 3D environment surrounding the cells, where cell adhesion, structure, effector transport and mechanotransduction are substantially altered. A carefully designed 3D model can provide more physiologically relevant information using experimental designs unachievable by conventional 2D assays at a fraction of the cost of in vivo models.
    Current 3D cell culture assays like hanging drop culture often lack the capability to organize different co-cultured cell types in a meaningful way. The application of chemical gradients or flow is usually not possible.
    We are now able to address this issue with a modular microfluidic platform that can co-culture multiple cell types in discrete 3D and 2D channels. Organotypic assays with animal model-like complexities using human cells have been developed for research, drug discovery & diagnostics. These include models for immune checkpoint, T-cell killing efficiency, angiogenesis, metastasis, cell migration, microvascular networks and the blood-brain barrier. Additional applications that focus on a liver model will also be discussed. Drug Induced Liver Injuries (DILI) contributes to drug failures, drug withdrawals and acute liver failures. The liver strongly interacts with other organ systems and in some instances the metabolites secreted by the liver are responsible for other organs' injury. Engineered 3D liver models may increase the physiological relevance of drug toxicity by maintaining the expression levels of key cytochrome P450 enzymes and metabolic activity in liver cells.
  • Making new connections – An overview of new TLC-MS Applications Session 1
    Making new connections – An overview of new TLC-MS Applications Session 1 Michaela Oberle Oct 23 2018 7:00 am UTC 75 mins
    In the last decade the trend for hyphenating different analytical techniques became an more and more important role in analytical labs. Combinations like LC-LC-MS or LC-MS-MS help to solve the analysis of complex samples in a proper way. The Analytical data which could be received are more sensitive focused on special analytes or give a better overview of the whole sample composition.

    This webinar should give the attendances an overview of the advantage and strength of (HP)TLC- MS coupling technique along various Applications from different analytical fields using different MS techniques. Tips and tricks for the right handling are be presented, to avoid main basic defaults.
  • Making new connections – An overview of new TLC-MS Applications Session 2
    Making new connections – An overview of new TLC-MS Applications Session 2 Michaela Oberle Oct 23 2018 2:00 pm UTC 75 mins
    In the last decade the trend for hyphenating different analytical techniques became an more and more important role in analytical labs. Combinations like LC-LC-MS or LC-MS-MS help to solve the analysis of complex samples in a proper way. The Analytical data which could be received are more sensitive focused on special analytes or give a better overview of the whole sample composition.

    This webinar should give the attendances an overview of the advantage and strength of (HP)TLC- MS coupling technique along various Applications from different analytical fields using different MS techniques. Tips and tricks for the right handling are be presented, to avoid main basic defaults.
  • Enhancing key PV Solutions to boost the efficiency of drug safety workflows
    Enhancing key PV Solutions to boost the efficiency of drug safety workflows Sherry Winter, Senior Solution Marketing Manager at Elsevier Oct 23 2018 2:00 pm UTC 75 mins
    Databases of peer-reviewed biomedical literature and regulatory documents are crucial sources for pharmacovigilance activities. When monitored properly, they yield drug safety signals that are essential for risk–benefit assessments and adverse event reports. However, both are vast resources that can be challenging to monitor efficiently and accurately, especially if different interfaces are needed to access each database.

    In 2018, Elsevier is enhancing key solutions for pharmaceutical R&D as part of ongoing efforts to improve the comprehensiveness, efficiency, accuracy and compliance of pharmacovigilance-focused research. By ensuring that all relevant information is captured efficiently, the company is helping drug safety and pharmacovigilance teams deliver considerable improvements in health-critical workflows.

    This webinar focuses on 2018 enhancements to Embase, PharmaPendium and QUOSA PV, showing how each solution offers dedicated means to boost the efficiency and accuracy of the monitoring of relevant databases, assessment of captured information, and supervision of the workflow. These enhancements include:
    - A dedicated Embase query form for efficient creation and validation of the complex search strings needed for high-recall, high-precision literature searching
    - An Embase French Local Language Module to extend the reach of Embase into specially selected French-language literature
    - More capabilities in PharmaPendium for searching the FDA Adverse Event Reporting System (FAERS)
    - Even more flexible means to run and oversee GxP-compliant workflows through QUOSA PV, with new functionalities for medical review, signal management and quality assurance. The webinar will address these solutions and enhancements in the context of comprehensive support for the goals of pharmacovigilance.
  • The Business Value and Bottom Line Impact of Taxonomy
    The Business Value and Bottom Line Impact of Taxonomy Seth Earley, CEO, EIS & Carla Pealer, Taxonomy Consultant, EIS Oct 24 2018 5:00 pm UTC 60 mins
    Business agility rests upon a well-architected environment of business processes, workflows, and communications.

    So how does taxonomy fit in? It’s everywhere - taxonomy is the foundational building block that improves efficiencies, collaboration, and cost reductions across the enterprise. And the more agile you are, the better opportunity you have to compete and win.

    In this webcat you will learn:

    • Industry-agnostic best practices to boost your bottom line and beat your competition through taxonomy design and semantic integration
    • How taxonomy design enables customer acquisition, search relevancy, structured data, faster time to market, asset reuse, and more.

    Speaker: Carla Pealer, Consultant, Earley Information Science
  • AU Analyzer Advanced Troubleshooting
    AU Analyzer Advanced Troubleshooting Lisa Hammett, Chemistry Product Manager, Beckman Coulter Oct 24 2018 6:00 pm UTC 45 mins
    In the AU Analyzer Advanced Troubleshooting webinar, the Reliability Improvement Team shares advanced troubleshooting techniques that can help laboratories ensure uptime and reliability of their AU chemistry analyzers. The helpful tools presented during this webinar are based on customer feedback gathered from technical support calls and field service support visits with technologists using our AU systems.

    The presentation is designed to provide you with useful practices and troubleshooting tips for maximum AU analyzer reliability and uptime. This includes an overview of:

    • Common items that can impact results
    • Key analyzer functions, reaction sequence and data calculation
    • Problem-solving techniques for optical density check flags
    • Troubleshooting methods for photocal and other errors

    P.A.C.E. credit and State of Florida CEUs are available for your participation.*

    About the speaker:
    Lisa Hammett holds a B.S. degree in medical technology from the University of Texas at Austin. For almost a decade, Lisa has served as a senior analyst in chemistry product management marketing with Beckman Coulter, specializing in AU chemistry systems. Prior to Beckman Coulter, Lisa served for 16 years as a course developer and customer trainer for AU analyzers with Olympus.

    *Beckman Coulter Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. These credits are recognized by the State of California. Most programs also provide State of Florida credits (with valid license number). At this time, we cannot issue continuing education credits for those who provide healthcare (or work for an institution that provides healthcare) in Massachusetts or Vermont.
  • Emerging Quantum Dot Materials: Synthesis and Application
    Emerging Quantum Dot Materials: Synthesis and Application Osman M. Bakr, PhD Oct 25 2018 1:00 pm UTC 75 mins
    Quantum Dots (QDs) undoubtedly attracted lots of interest with their superior luminescent properties. What is distinct about their luminescent properties is that the wavelengths of emitted light can be precisely tuned by changing of nanoparticle size or composition. Quantum dots possess narrow full width at half maximum (FWHM), high photoluminescence quantum yield (PLQY), emission wavelength tunability through the entire visible and near IR range. In this webinar, we talk about synthesis and application of emerging quantum dots materials: Perovskite and PbS QDs. Perovskite QDs emit light within the visible range, have high PLQY (up to 100 %), narrow FWHM (below 20-25 nm), and are considered as the best alternatives for CdSe and InP QDs for display application. PbS QDs emit light in near IR region with narrow FWHM of absorption and emission, making them ideal in NIR photodetectors and solar cells.
  • Safety First Throughout the Histology Workflow
    Safety First Throughout the Histology Workflow Shalmica Jackson, PhD Oct 25 2018 4:00 pm UTC 75 mins
    From tissue processing to slide coverslipping, the histology workflow is laden with hazardous steps. Chemical sensitizers, strong acids, alkaline substances, and oxidizing agents are routinely used during histological workflows. These classes of chemicals are known to damage and even destroy living tissues. Ensuring the safety of laboratory workers is of the utmost importance. This workshop will present new approaches to help make the histopathology laboratory a safer environment with the use of formalin-free fixatives, phenol-free stains, DBP-free mounting media, IVD-certified ready-to-use reagents, and more.
  • High Precision PCR utilizing ThermaGenix Reagents
    High Precision PCR utilizing ThermaGenix Reagents Professor Lawrence Wangh, Founder and CSO of ThermaGenix, Inc. Oct 30 2018 3:00 pm UTC 60 mins
    The polymerase chain reaction (PCR) is a mainstay of molecular biology and genomics that provides an efficient and rapid in vitro method for enzymatic amplification of DNA or RNA sequences from various sources. There are three unique, easy-to-use PCR additives that act at different temperatures to improve sensitivity and product yield by preventing mis-priming:

    1. ThermaStop™: a novel reagent that acts like a universal hot-start for Type A and Type B DNA polymerases
    2. ThermaGo™: a unique reagent that enhances the specificity of these same enzymes during the course of amplification
    3. ThermaStop™-RT: a first-in-class reagent that acts like a hot-start for many reverse transcriptases.

    Each reagent is a chemically modified oligonucleotide produced under GMP conditions and sold as a dry powder. Stable at room temperature, each reagent can simply be added to the enzyme of your choice prior to adding that enzyme/reagent complex to the master mix. These improvements are observed for both inexpensive Type A Taq polymerases and very expensive HiFi Type B DNA polymerases in applications such as qPCR, multiplexing, and preparation of DNA amplicons prior to next-generation sequencing (NGS).
  • Get off Your Lazy NAS by Transforming Your Data Management Strategy
    Get off Your Lazy NAS by Transforming Your Data Management Strategy Stefaan Vervaet, Sr. Director, DCS Solutions & Alliances, Western Digital; Krishna Subramanian, COO, Komprise Oct 30 2018 5:00 pm UTC 30 mins
    NAS is essential to your IT environment, but a lazy NAS can hurt performance, cause you extra work and bust your budget.

    Join experts from Western Digital and Komprise to learn how to transform your data management strategy by gaining visibility and an understanding of your data, automating the movement of inactive data to less expensive storage and optimizing your storage environment.

    In this webinar you’ll learn how to:
    •Increase NAS performance
    •Free up NAS capacity
    •Reduce costs by up to 50% or more
    •Reduce backup times by up to 60 percent or more

    A small investment of time can deliver BIG cost savings!
  • Introducing Embase French Local Literature Module
    Introducing Embase French Local Literature Module Yvonne van de Vrede, Embase Product Manager Oct 31 2018 3:00 pm UTC 75 mins
    Please note the new date and time

    Literature is one of the essential sources to identify high quality ADR reports. Regulatory authorities require companies to monitor major international publications through databases, as well as local, non-English content sources in each of the countries where the drugs are marketed. Currently, the local, non-English content sources is not available in most international literature databases, therefore screening, reviewing and monitoring this type of literature costs extra time, money and creates an additional compliance risk.

    In this webinar, Embase product manager Yvonne van de Vrede will discuss:
    -The challenges in Local Literature Monitoring process for pharmacovigilance, with a focus on the French market
    -The concepts of Embase French Local Literature Module
    -How to use this module in Embase.com to build effective searches to identify the mention of drugs and ADRs in French journals

    About Speaker:
    Yvonne van de Vrede has a degree in Molecular Pharmacology from the Free University in Amsterdam and a French MSc equivalence in Neurosciences from the University Paris VI. She started working for Elsevier in 2002 and has dealt with Embase in different roles: as an Index Quality Manager, a Thesaurus development manager, Account Manager and as a Project Manager. Since 2016, she has worked as Embase Product Manager for the content coverage and development, customer engagement and vendor relationship.
  • How to accelerate FTO searches on sequences by 70%
    How to accelerate FTO searches on sequences by 70% Jessie Parker @ PatSnap Oct 31 2018 4:00 pm UTC 60 mins
    Scientists in the biotech and pharma industries spend a large amount of time and resources on researching sequences. However, often as researches progress to the later stages of R&D, they become blocked by competitors and products that are already on the market.

    Using a sequence searching tool which links to patent data can help you identify obstacles and freedom to operate much earlier on. Having access to a full data set sooner, can help you save time, money and enhance your R&D.

    Join this webinar to find out how you can accelerate FTO searches on your sequences.
  • Advances and Challenges in Vaccine Development and Manufacture
    Advances and Challenges in Vaccine Development and Manufacture Tony D’Amore, Sanofi Pasteur Nov 2 2018 2:00 pm UTC 75 mins
    This webinar reviews the constraints and complexities of vaccine product development and manufacture.
    The evolution of bioprocess and analytics innovation and technologies to overcome these challenges are discussed.
    The strategy and leveraging of innovation and technology for rapid product development and accelerating timelines is described.
    Case studies to illustrate the advances in vaccine development and manufacture are illustrated.
    A look into the future with state of the art technologies.
  • What's new in PharmaPendium?
    What's new in PharmaPendium? Pooja Jain Nov 6 2018 3:00 pm UTC 60 mins
    Successful drug development requires anticipating safety and regulatory issues as early as possible. PharmaPendium is uniquely positioned to facilitate efficient translational studies of drug safety and efficacy. It supports risk assessment activities with unique access to valuable adverse event and approval documents alongside tools that maximise insights into drug safety and efficacy data.

    The 2018 development plan for PharmaPendium focused on strengthening this position as a support tool for early assessments of drug candidates.

    About this webinar
    Join PharmaPendium Product Manager Pooja Jain to discover the new features that facilitate efficient translational studies of drug safety and efficacy, including:

    - New search and filter capabilities that enable users to specifically search for pharmacokinetic, metabolizing enzyme and transporter data for concomitant drugs and other substances
    - Improvements to PharmaPendium’s unique FDA Adverse Event Reporting System (FAERS) search functionality, including a heatmap and percentage calculator, which make it easier to visualize and compare differences in adverse event reporting
    - Updates to the Drug–Drug Indication Risk Calculator (DDIRC) content to keep pace with user needs for drug–drug interaction (DDI) risk prediction
    - Updates to the MedDRA (Medical Dictionary for Regulatory Activities) taxonomy, which helps ensure that searches conform to the clinically validated international nomenclature used by regulatory authorities
    -Improvements to the Indications taxonomy and search capabilities that provide insight into approved vs tested/off-label indications
    - Email alerts to help users stay up to date on new content relevant for a given search

    The webinar includes demonstrations of all the new features and a Q&A session for attendees to get further information about PharmaPendium’s drug safety and efficacy workflows.
  • Protein Sample Prep Tips & Tricks
    Protein Sample Prep Tips & Tricks Natasha L. Pirman, Ph.D. Nov 7 2018 4:00 pm UTC 75 mins
    E. coli is the most widely used recombinant expression system to overexpress protein given that it is inexpensive, easy to scale up, and relatively fast. Due to its wide-spread use, there are numerous molecular tools, products, and expression/purification protocols available. Determining which tools and products to use, such as plasmid, strain-type, affinity tag and resin system, or buffer exchange device can be daunting. Here, we present a workflow overview of the recombinant protein expression from E. coli and provide insight and various tips and tricks about how to optimize and improve protein yield and purity enabling you to make the best decisions for your protein of interest.
  • FBI Warning: Cyber Attacks on ATMs - Are you prepared?
    FBI Warning: Cyber Attacks on ATMs - Are you prepared? Joan McGowan, Senior Analyst at Celent, Steve Migliore, Head, Cybersecurity at Unisys, Larry Andrews, FS Director at Unisys Nov 7 2018 6:00 pm UTC 75 mins
    A recent warning issued to banks by the FBI reads like the script for a Hollywood movie: cybercriminals are plotting a sophisticated, global “ATM cash-out” using cloned credit cards to fraudulently withdraw millions of dollars in just a few hours. A few days later, reports of a $13.5 million heist of 25 ATMs across the globe confirmed the reality that ATMs are a prime target for hackers.

    Are you prepared for when an ATM breach occurs, or more importantly, when a hacker gains access to your network and confidential customer information through your ATM networks?

    Join Unisys and Celent for this very critical, time sensitive topic that will help you understand this increasing threat and how to respond.

    In this webinar we will cover:

    •How global trends, such as open banking, will increase these threats
    •How ATM security fits in your end to end security and risk posture
    •We will be discussing Unisys Stealth®, which is a flexible software suite that leverages microsegmentation to secure critical assets
    •And so much more!
  • Regulatory Approval of Three Rapid Microbiological Methods for MACI Product Rele
    Regulatory Approval of Three Rapid Microbiological Methods for MACI Product Rele John Duguid, Senior Director, at Vericel Corporation in Cambridge, and Nicola Reid, Senior Product Manager at Charles River Nov 8 2018 3:00 pm UTC 75 mins
    Title:Regulatory Approval of Three Rapid Microbiological Methods for MACI Product Release

    Rapid detection of contaminants is essential for cell therapy products with short shelf lives. Integrating quality into the process through lot segregation, raw material qualification, environmental control, personnel training, and detailed procedures is critical because final results for conventional microbiological tests may not be available prior to product release or patient administration. EMA approval of the MACI MAA in 2013 followed by US FDA BLA approval in 2016 included three RMM product release assays for sterility, endotoxin, and mycoplasma.
  • Cell Culture in 3D Systems; Moving from a 2D to 3D Environment
    Cell Culture in 3D Systems; Moving from a 2D to 3D Environment Seth Hanson, Academic Research Technology Specialist - Merck KGaA, Darmstadt, Germany Nov 9 2018 2:00 am UTC 75 mins
    Cell culture in 3D systems: moving from 2D to 3D cell culture?
    It’s now well accepted by the scientific community that the 3D cell culture condition better recapitulate the in vivo environment and behaviours of cells. But it’s not a trivial change to move from 2D cell culture conditions to 3D, and not always easy to choose the right system to use.

    An understanding of the key parameters for 2D and 3D cell culture will be reviewed, followed by an overview of the technologies available at Merck with features, benefits, and application data.
  • Efficiency by Design- Case Study for a Hybrid Clinical Manufacturing Facility
    Efficiency by Design- Case Study for a Hybrid Clinical Manufacturing Facility Dr Sourav Kundu, Senior Director at Teva Pharmaceuticals Global Biologics R&D and Adam Kaletski, Business Leader, Bioprocess Nov 9 2018 3:00 pm UTC 75 mins
    · Facility needs and characteristics for clinical manufacturing
    · Single-use or stainless steel?
    · When to use single-use equipment
    · Hybrid manufacturing facilities – best of both worlds
    · Teva’s clinical manufacturing facility – attributes, layout, construction, qualification, choice of equipment
    · Final thoughts
  • Literature searching in Health Economics
    Literature searching in Health Economics Julie Glanville, Associate Director at York Health Economics Consortium Nov 14 2018 3:00 am UTC 75 mins
    Julie Glanville is Associate Director at York Health Economics Consortium, part of the University of York. Here, she manages systematic review and literature review projects. She also organizes the YHEC training programme.

    YHEC provides a range of research services including literature searches and evidence identification to inform research projects in healthcare topics but also in other fields such as food safety and feed safety, social care, housing, criminal justice and education. YHEC contributes to the evidence base for information retrieval with a special focus on identifying economic evidence and search filters (strategies) for a range of research methods.

    YHEC carries out systematic and non-systematic reviews for a range of clients to identify the effects of drugs, devices and other interventions. The training program also partners with Quantics Consulting to provide indirect treatment comparisons (ITCs) and mixed treatment comparisons (MTCs).
  • Por que a segurança importa?  Perspectivas globais e locais do Unisys Security
    Por que a segurança importa? Perspectivas globais e locais do Unisys Security Leonardo Carissimi, Security Solutions Director, Unisys Latin America Nov 14 2018 1:00 pm UTC 60 mins
    Unisys Security Index é uma importante pesquisa sobre preocupações de segurança realizadas em todo o mundo. Lançado globalmente em 2007, fornece uma medida regular e estatisticamente sólida das preocupações que os consumidores em 13 países têm sobre os principais aspectos da segurança, incluindo segurança nacional, financeira, pessoal e cibernética.
    Participe deste webinar para ouvir Leonardo Carissimi, diretor de Segurança Cibernética da Unisys América Latina, compartilhar os resultados e fatos da pesquisa sobre as preocupações de segurança dos consumidores do Brasil.
    Leonardo usará os resultados deste ano, justapostos com mais de uma década de histórico de pesquisas para fornecer um relatório convincente sobre o estado de segurança da perspectiva que mais importa: o usuário.
  • ¿Por qué importa la seguridad?  Perspectivas de Latinoamérica de Unisys Security
    ¿Por qué importa la seguridad? Perspectivas de Latinoamérica de Unisys Security Leonardo Carissimi, Security Solutions Director, Unisys Latin America Nov 14 2018 8:30 pm UTC 60 mins
    Unisys Security Index es una importante encuesta regular de las preocupaciones de seguridad llevada a cabo en todo el mundo. Lanzada a nivel mundial desde 2007, proporciona una medida regular y estadísticamente sólida de las preocupaciones que tienen los consumidores de 13 países con respecto a los principales aspectos de la seguridad, incluyendo seguridad nacional, financiera, personal y ciber seguridad.
    Únase a este webinar para escuchar a Leonardo Carissimi, director de Ciberseguridad para Unisys América Latina, compartir los resultados y realidades de la encuesta sobre de las preocupaciones de seguridad de los consumidores en Argentina, Colombia y México.
    Leonardo usará los resultados de este año, yuxtapuestos con más de una década de historial de encuestas realizadas para proporcionar un informe convincente sobre el estado de la seguridad desde la perspectiva que más importa: la del usuario.
  • Mixed mode Chromatography in Purifying biologics - Overview
    Mixed mode Chromatography in Purifying biologics - Overview Vivek Halan Zumutor Biologics Pvt Ltd, Bangalore, India Nov 15 2018 9:30 am UTC 75 mins
    This Webinar will discuss MMC in purifying biologics which includes monoclonal antibodies (mAbs), Bispecific antibodies (BsAbs), antibody fragments (Scfv,Fab) and other recombinant proåteins. My discussion is intended for audience from biopharmaceutical industry as well as active collaborators from academic institutes.
  • More Success in LC-MS: Tips and Tricks for Sample & Mobile Phase Preparation and
    More Success in LC-MS: Tips and Tricks for Sample & Mobile Phase Preparation and Vivek Joshi, PhD Nov 15 2018 4:00 pm UTC 75 mins
    LC-MS is one of the most commonly used analytical techniques in various sectors for quantitation and identification of unknown from variety of complex samples. Use of LC-MS has expanded over the years as it offers both selectivity and specificity in analysis. With advances in both chromatography and mass spectrometry, sensitivity and accuracy of this technique has further increased, allowing for detection and identification of low-level analytes in complex sample matrices.

    The LC-MS workflow has three main components, which determine successful analyses: sample preparation, choice of mobile phase components and column selection. Not paying enough attention to one of these components can complicate data analysis, quantitation and identification.

    In this seminar, you will learn critical factors to consider when selecting the sample preparation methods, mobile phase components and HPLC columns.
  • Evolve Manufacturing Processes by Implementing Disruptive Technologies
    Evolve Manufacturing Processes by Implementing Disruptive Technologies Yuyi Shen PhD, Principal Scientist, Grifols, John Cyganowski, Director of Manufacturing Sciences and Technologies Downstream Nov 19 2018 5:00 pm UTC 75 mins
    The desire for innovative technology that can eventually cause disruptive improvement remains high in the biotech pharmaceutical industry. The road between pursuing and developing that technology to genuine implementing is not a smooth ride. In this webinar, the presenter identifies key challenges of implementing innovative technologies and the major drive for implementing innovative technologies and process upgrades. The presenter will share some case studies of implementing successful innovation tools and provide comparative economic analysis based on the understanding the true value of innovation driven process design. The webinar also provide the insight of the balance needs for quality, cost and speed.